Global Drug Facility adds new TB drug to its catalogue
31-10-2019
Federal Circuit rules against J&J in Zytiga dispute
16-05-2019
sundryphotography / Shutterstock.com
Johnson & Johnson (J&J) has committed $500 million to research and development programmes over the next four years in a bid to eliminate HIV and tuberculosis (TB) across the world by 2030.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Johnson & Johnson, HIV, Tuberculosis, research and development, vaccines, JAnssen, infectious disease
